Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Enzastaurin plus R-CHOP in DLBCL
NCT00451178Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- May 2007
- Primary completion
- Feb 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of enzastaurin in diffuse large B-cell lymphoma (DLBCL) (2 arms), sponsored by Eli Lilly and Company. Primary endpoint: Progression-Free Survival Time up to 55 months. Started May 2007; status: completed.
02
Drugs
enzastaurin
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT00451178.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00451178.